Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,405.20
(
-2.38%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
106.89
(
0.00%
)
Bitcoin
66,681.93
(
0.52%
)
News Focus
News Focus
Post# of 257302
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122817
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 225743

Thursday, 10/24/2019 4:57:08 PM

Thursday, October 24, 2019 4:57:08 PM

Post# of 257302
GILD 3Q19 HCV results:

https://www.businesswire.com/news/home/20191024005897/en

3Q19 GAAP HCV sales were $674M, but the actual product sales of GILD’s three HCV regimens were $703M; the “missing” $29M in the GAAP total was due to a statutory clawback in the EU.

The $703M figure was -8% relative to the adjusted 2Q19 figure of $762M (excluding the $80M true-up reported in 2Q19 as described in #msg-150227808).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today